With the introduction of Amgen's Amjevita, AbbVie's Humira loses its 2 decades of exclusivity. A slate of other Humira biosimilars are set to drop this year as well, with prices set to drop due to competition. However, the changes may be slow to take effect, as several factors are set to complicate the process of reimbursement and uptake.
According to Zachary Brennan, “Forecasts of how much the US will save from new competition need to be tempered with the fact that AbbVie has raised the price of Humira by nearly 500% from 2013 to 2021, and as AbbVie has closed off certain markets so its competitors cannot gain access.”
To read more, click here.
(Source: Endpoints News, January 30th, 2023)
